Weatherden Symposium 2026

Partner Jackie Mulryne will be a speaker at the Weatherden Symposium 2026 on Women's Health. The symposium will focus on what it takes to move from promising science to programs that regulators accept, investors support, and ultimately deliver for patients, with the aim to build development strategies that stand up scientifically, regulatorily, and commercially — getting more therapies to women, and faster.

Women's health is one of the largest underdeveloped opportunities in life sciences, and the scientific, clinical, and commercial infrastructure supporting innovation in this space has historically lagged disease burden. Therapeutic areas such as obesity and oncology, fields once considered scientifically complex or commercially uncertain, have become established areas of investment once biological understanding, clinical development strategy, and regulatory pathways mature. Women's health is now approaching a similar inflection point.

Weatherden is convening leaders from across biotechnology, pharma, investment and academia to explore how smarter clinical development and regulatory strategy can unlock the next wave of innovation in women's health.

This event will bring together leaders from across the ecosystem to explore how the thoughtful application of development strategies utilized in more established therapeutic areas can unlock both clinical impact and commercial viability, and reframe women's health as a central, scalable, and scientifically rigorous domain.

Expert panelists will include biopharma leaders who are actively shaping the development and commercialization of next-generation therapies in women's health.